TREMFYA®▼ (guselkumab) Induces Clinical and Endoscopic Improvements in Patients with Moderately to Severely Active Crohn’s Disease based on Interim Results from Phase 2 Study
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced Phase 2 interim data from the GALAXI 1 study, which showed TREMFYA® ▼ (guselkumab) demonstrated results at week 12 in adult patients with moderately to severely active Crohn’s disease (CD) with inadequate response or intolerance to conventional therapies and/or biologics.1 At 12 weeks, guselkumab induced significantly greater improvements compared to placebo across key clinical and endoscopic outcome measures, with a safety profile consistent with approved indications.1 Guselkumab is not currently approved for the treatment of CD in the European Union (EU).2
These new data are being presented today as an oral presentation (Abstract OP089) at the 28th United European Gastroenterology (UEG) Week, which is conducting its annual congress virtually.1
“While there have been substantial treatment breakthroughs in Crohn’s disease, there are still patients who are not gaining benefit from any of the currently approved mechanisms of action for their symptoms,” said lead study investigator William J. Sandborn,* M.D., Chief of Gastroenterology, Professor of Medicine, University of California, San Diego, who is delivering the oral presentation virtually at UEG Week. “I am encouraged by these early data, which show that guselkumab across three different dosing groups induced a significant response in key clinical and endoscopic outcome measures in Crohn’s disease.”
GALAXI 1 evaluated the efficacy and safety of guselkumab compared with placebo in CD. The interim analyses reported results through week 12 from the first 250 patients enrolled. Approximately 50 percent of patients had previously failed biologic therapy; and baseline disease characteristics were consistent with moderately to severely active CD (Crohn’s Disease Activity Index [CDAI], mean 306.6; Simple Endoscopic Score for Crohn’s Disease [SES-CD], median 11.0). Patients were randomised equally into five treatment arms, including treatment with guselkumab dosed at 200, 600 or 1200 mg intravenously (IV) at weeks 0, 4 and 8, respectively; or treatment with ustekinumab dosed at ~6 mg/kg IV at week 0 and then dosed at 90 mg subcutaneously at week 8; or placebo.1
At week 12, there were significantly greater reductions from baseline in the CDAI observed in each guselkumab group (200, 600 or 1200 mg IV doses) compared with placebo (Least Squares [LS] means: -154.1, -144.3 and -149.5 versus -36.0, respectively; all p<0.001). a significantly higher proportion of patients assigned to each guselkumab dose achieved clinical remission compared with placebo 54.0 percent, 56.0 50.0 respectively, versus 15.7 percent among conventional therapy failures, 61.6 in the guselkumab-combined group 18.5 treated at week> Among patients who had previously failed biologic therapy, 45.5 percent in the guselkumab-combined group compared with 12.5 percent in the placebo group achieved clinical remission at week 12.1 0.001).>
Furthermore, at week 12, a significantly higher proportion of patients treated with guselkumab achieved clinical response (p<0.001), 12 patient reported outcome (pro)-2 remission clinical-biomarker response and endoscopic compared with patients treated placebo. healing is an important for long-term disease control; 37.3 percent of in the guselkumab-combined group 11.8 placebo achieved after only weeks induction treatment>1 0.001),>
“For patients living with moderately to severely active Crohn’s disease, including those who have not had an adequate response or have intolerance to other therapies, these results show that guselkumab may play an important role as a new treatment option pending results from the ongoing registration trials,” said Jan Wehkamp, M.D., Vice President, Gastroenterology Disease Area Leader, Janssen Research & Development, LLC. “Although more research is needed, we are encouraged by the data and the potential role for selective IL-23 inhibition in helping patients manage their Crohn’s disease symptoms and treating the underlying disease process.”
Guselkumab demonstrated a safety profile consistent with that established from prior clinical trials across approved indications. Observed adverse events (AEs) were generally similar amongst treatment groups and placebo through week 12. In the guselkumab 200, 600, 1200 mg IV and placebo treatment groups, serious AEs occurred in 4 percent, 4 percent, 2 percent and 4 percent, and serious infections occurred in 2 percent, 0 percent, 0 percent and 0 percent of patients, respectively. There were no reported deaths in guselkumab-treated patients, and no guselkumab-treated patient had active tuberculosis, serious hypersensitivity reactions or malignancies.1 Very common (>10%) and common AEs (>1%) in controlled periods of clinical studies with guselkumab were upper respiratory infections, gastroenteritis, herpes simplex infections, tinea infections, headache, diarrhoea, urticaria, arthralgia and injection site reactions. Uncommon AEs observed were hypersensitivity, anaphylaxis and rash.2
About the GALAXI 1 trial1,3
GALAXI 1 is a double-blind, placebo-controlled, multicentre Phase 2 dose-ranging study evaluating the efficacy and safety of guselkumab in patients with moderately to severely active Crohn’s disease with inadequate response/intolerance to conventional therapies (corticosteroid, immunosuppressive) and/or biologics (TNF antagonist, vedolizumab). Patients will receive treatment through up to 3 years.
Interim analyses at week 12 evaluated the key outcomes of change in CDAI score from baseline, clinical remission (CDAI<150), clinical response (decrease from baseline in cdai ≥100 or pro-2 remission (abdominal pain mean daily score ≤1 and stool frequency ≤3), biomarker (clinical ≥50% reduction c-reactive protein fecal calprotectin), endoscopic (≥50% improvement the ses-cd), safety patients treated with guselkumab compared placebo. efficacy of reference arm (ustekinumab) placebo was also evaluated demonstrated. p>
About Crohn’s disease (CD)
CD is one of the two main forms of inflammatory bowel disease, which affects up to 2 million people across Europe.4 CD is a chronic inflammatory condition of the gastrointestinal tract with no known cause, but the disease is associated with abnormalities of the immune system that could be triggered by a genetic predisposition, diet or other environmental factors.5 Symptoms of CD can vary but often include abdominal pain and tenderness, frequent diarrhoea, rectal bleeding, weight loss and fever.5,6 There is currently no cure for CD.7
About TREMFYA® (guselkumab)
Developed by Janssen, guselkumab is the first approved fully human monoclonal antibody that selectively binds to the p19 subunit of interleukin (IL)-23 and inhibits its interaction with the IL-23 receptor.2 Guselkumab is approved in the EU, US, Canada, Japan and a number of other countries worldwide for the treatment of adult patients with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet [UV] light).2 It is approved in the US, Canada, Japan, Brazil and Ecuador for the treatment of adult patients with active psoriatic arthritis.2 IL-23 is an important driver of the pathogenesis of immune-mediated inflammatory diseases such as psoriasis.8 Guselkumab is administered as a 100 mg subcutaneous injection once every 8 weeks, after starter doses at weeks 0 and 4.2
The Janssen Pharmaceutical Companies of Johnson & Johnson maintain exclusive worldwide marketing rights to TREMFYA® .
Important Safety Information2
Very common (>10%) and common AEs (>1%) in controlled periods of clinical studies with guselkumab were upper respiratory infections, gastroenteritis, herpes simplex infections, tinea infections, headache, diarrhoea, urticaria, arthralgia and injection site reactions. Uncommon AEs observed were hypersensitivity, anaphylaxis and rash. Most were considered to be mild and did not necessitate discontinuation of study treatment.
Please refer to the Summary of Product Characteristics for full prescribing information for guselkumab: https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya#product-information-section .
▼ AEs should be reported. This medicinal product is subject to additional monitoring and it is, therefore, important to report any suspected AEs related to this medicinal product. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. AEs should also be reported to Janssen-Cilag Ltd on 01494 567447.
About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
Learn more at www.janssen.com/emea .
Follow us at www.twitter.com/JanssenEMEA .
Janssen-Cilag International NV, the marketing authorisation holder for TREMFYA® in the EU, and Janssen Research & Development, LLC, are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the Phase 2 Week 12 interim study of TREMFYA® (guselkumab) in Crohn’s disease. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialise, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behaviour and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
* Dr William J. Sandborn is a paid consultant for Janssen. He has not been compensated for any media work.
- Sandborn, W, et al . The Efficacy and Safety of Guselkumab Induction Therapy in Patients with Moderately to Severely Active Crohn’s Disease: Week 12 Interim Analyses from the Phase 2 GALAXI 1 Study (Abstract OP089). Presented at the UEG Week Virtual 2020 Congress October 11–13.
- European Medicines Agency. TREMFYA Summary of Product Characteristics. 2019. Available at: https://www.medicines.org.uk/emc/medicine/34321 . Accessed October 2020.
- Clinicaltrials.gov. A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (GALAXI). Identifier: NCT03466411. Available at: https://clinicaltrials.gov/ct2/show/record/NCT03466411 . Accessed October 2020.
- Ng SC, et al . Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet 2017;390:2769-2778.
- Crohn’s and Colitis Foundation. Causes of Crohn’s disease. Available at: https://www.crohnscolitisfoundation.org/what-is-crohns-disease/causes . Accessed October 2020.
- Crohn’s and Colitis Foundation. Overview of Crohn’s disease. Available at: https://www.crohnscolitisfoundation.org/what-is-crohns-disease/overview . Accessed October 2020.
- Mayo Clinic. Crohn’s disease. Available at https://www.mayoclinic.org/diseases-conditions/crohns-disease/symptoms-causes/syc-20353304 . Accessed October 2020.
- Benson JM, et al. Discovery and Mechanism of Ustekinumab. MAbs 2011;3:535.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DIGITAL-VAULT-SERVICES19.1.2021 20:44:44 CET | Press release
Digital Vault Services GmbH launches its market solution for Digital Guarantees
CO-JOHNS-MANVILLE19.1.2021 20:02:43 CET | Press release
Johns Manville Announces Katie Albery as New General Counsel
MA-LOOMIS-SAYLES19.1.2021 18:06:48 CET | Press release
Loomis Sayles Welcomes Marques Benton as Chief Diversity, Equity and Inclusion Officer
MAXON19.1.2021 16:52:50 CET | Press release
Maxon Announces the Acquisition of Japanese Distributor Business
PITNEY-BOWES-INC.19.1.2021 15:02:42 CET | Press release
Pitney Bowes Appoints Ana Maria Chadwick as Executive Vice President and Chief Financial Officer
CA-GLOBALITY19.1.2021 14:02:48 CET | Press release
Globality, the World’s First Smart Sourcing Platform Powered by AI, Raises $138.3 Million of Series E Funding From Sienna Capital, a Wholly Owned Subsidiary of Groupe Bruxelles Lambert, and the SoftBank Vision Fund
CA-ZYNGA19.1.2021 14:02:48 CET | Press release
Zynga Launches Harry Potter: Puzzles & Spells in South Korea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom